Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2012

View Archived Issues

Taisho Pharmaceutical announces new GlyT1 inhibitors

New Exp1 inhibitors show promise in a number of in vitro and in vivo cancer studies

Morphotek evaluates MORAb-004 in new phase II trial

BioAlliance plans phase II Clonidine Lauriad study expansion

FDA requests more information for HyQ BLA

PRINT nanofabrication allows precision synthesis of therapeutic particles

Merck & Co. selects lead from new series of phosphodiesterase 10A inhibitors

Sanofi presents novel oncolytic drug candidate

Preclinical results demonstrate significant early antitumor efficacy of new immunotherapy

Johnson & Johnson reviews progress of first quarter 2012

DFH Pharma and NIH collaborate on development of HIV drugs

Abbott in-licenses Stanford University biomarkers for prostate cancer

Dyax and Eclipse Therapeutics enter licensing agreement

Highly potent and selective EZH2 inhibitors discovered by GSK

Depomed plans NDA filing for Serada

Novel ERK inhibitors designed

Novel PI3Kalpha/mTOR inhibitors developed at Hutchison MediPharma

Exelixis scientists discover new JAK1 inhibitors

New lysophospholipid S1P1 receptor agonists patented

Treatment begins in phase II IMO-3100 trial

Melanoma trial of SCIB-1 clear to advance to phase II

Intellect Neurosciences collaborates with leading Alzheimer's research group

AMRI enters into development and manufacturing deal

ImmunoGen reports advances in its anticancer drug pipeline

GE Healthcare enters Alzheimer's disease collaboration

Confirmatory data support efficacy of Phytopharm ALS candidate drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...